GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Horizon Therapeutics PLC (NAS:HZNP) » Definitions » Cyclically Adjusted PB Ratio

Horizon Therapeutics (Horizon Therapeutics) Cyclically Adjusted PB Ratio : 9.76 (As of May. 22, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Horizon Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-05-22), Horizon Therapeutics's current share price is $116.30. Horizon Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2023 was $11.91. Horizon Therapeutics's Cyclically Adjusted PB Ratio for today is 9.76.

The historical rank and industry rank for Horizon Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

HZNP' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 2.32   Med: 8.94   Max: 16.54
Current: 9.76

During the past years, Horizon Therapeutics's highest Cyclically Adjusted PB Ratio was 16.54. The lowest was 2.32. And the median was 8.94.

HZNP's Cyclically Adjusted PB Ratio is not ranked
in the Drug Manufacturers industry.
Industry Median: 1.88 vs HZNP: 9.76

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Horizon Therapeutics's adjusted book value per share data for the three months ended in Jun. 2023 was $23.198. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $11.91 for the trailing ten years ended in Jun. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Horizon Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Horizon Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Horizon Therapeutics Cyclically Adjusted PB Ratio Chart

Horizon Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.48 4.33 12.07 13.77 10.88

Horizon Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.64 6.33 10.88 9.77 8.63

Competitive Comparison of Horizon Therapeutics's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - General subindustry, Horizon Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Horizon Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Horizon Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Horizon Therapeutics's Cyclically Adjusted PB Ratio falls into.



Horizon Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Horizon Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=116.30/11.91
=9.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Horizon Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2023 is calculated as:

For example, Horizon Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2023 was:

Adj_Book=Book Value per Share/CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=23.198/119.6619*119.6619
=23.198

Current CPI (Jun. 2023) = 119.6619.

Horizon Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201309 1.061 100.274 1.266
201312 -0.743 99.875 -0.890
201403 -3.210 100.573 -3.819
201406 1.086 100.773 1.290
201409 4.590 100.474 5.467
201412 4.355 99.576 5.233
201503 5.161 99.975 6.177
201506 7.919 100.573 9.422
201509 7.901 100.274 9.429
201512 8.223 99.676 9.872
201603 8.062 99.676 9.678
201606 8.325 101.072 9.856
201609 8.447 100.274 10.080
201612 7.819 99.676 9.387
201703 7.414 100.374 8.839
201706 6.299 100.673 7.487
201709 6.102 100.474 7.267
201712 6.091 100.075 7.283
201803 5.220 100.573 6.211
201806 5.163 101.072 6.113
201809 5.473 101.371 6.461
201812 7.048 100.773 8.369
201903 8.141 101.670 9.582
201906 8.173 102.168 9.572
201909 8.328 102.268 9.744
201912 11.624 102.068 13.628
202003 11.483 102.367 13.423
202006 11.833 101.769 13.913
202009 17.210 101.072 20.375
202012 18.187 101.072 21.532
202103 17.160 102.367 20.059
202106 18.048 103.364 20.894
202109 19.635 104.859 22.407
202112 20.549 106.653 23.055
202203 20.994 109.245 22.996
202206 21.471 112.779 22.781
202209 22.011 113.504 23.205
202212 22.321 115.436 23.138
202303 22.293 117.609 22.682
202306 23.198 119.662 23.198

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Horizon Therapeutics  (NAS:HZNP) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Horizon Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Horizon Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Horizon Therapeutics (Horizon Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
70 St. Stephen’s Green, Dublin, IRL, D02 E2X4
Horizon Therapeutics PLC is a biotechnology company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Some of its pipeline products include UPLIZNA; HZN-825; Dazodalibep; Daxdilimab; TEPEZZA and others.
Executives
Andy Pasternak officer: EVP and Chief Business Officer C/O HORIZON THERAPEUTICS PLC, CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD, DUBLIN L2 D04 C5Y6
Aaron Cox officer: EVP, Chief Financial Officer C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4
Jeffrey W Sherman officer: EVP & Chief Medical Officer C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Patrick Mcilvenny officer: Chief Accounting Officer C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4
Sean M. Clayton officer: EVP, General Counsel C/O HORIZON THERAPEUTICS PLC, 70 SAINT STEPHENS GREEN, DUBLIN L2 D02 E2X4
Thompson Elizabeth H.z. officer: EVP, Research & Development C/O HORIZON THERAPEUTICS, INC., 2 TOWER PLACE, 12TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Timothy P Walbert director, officer: President, Chairman and CEO 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Jacopo Leonardi officer: Chief Commercial Officer C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4
Paul W. Hoelscher officer: EVP Finance 1 HORIZON WAY, C/O HORIZON THERAPEUTICS, INC., DEERFIELD IL 60015
Michael A. Desjardin officer: EVP, Technical Operations C/O JAZZ PHARMACEUTICALS, INC., 3180 PORTER DRIVE, PALO ALTO CA 94304
Miles W Mchugh officer: Principal Accounting Officer C/O ACCRETIVE HEALTH, INC., 401 N. MICHIGAN AVE, SUITE 2700, CHICAGO IL 60611
Barry Moze officer: EVP, Corporate Dev't. C/O HORIZON PHARMA, INC., 520 EAST COOK ROAD, SUITE 520, DEERFIELD IL 60015
Brian K Beeler officer: EVP, General Counsel C/O HORIZON PHARMA PLC, 520 LAKE COOK ROAD, SUITE 520, DEERFIELD IL 60015
Michael G Grey director C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121
William F Daniel director TREASURY BUILDING, LOWER GRAND CANAL STREET, DUBLIN 2 L2 00000